Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.
A first-in-class outer-membrane protein target: it binds LptD to block lipopolysaccharide transport in Pseudomonas.
Also known as: POL7080 · RG7929
Part of the Foundational & therapeutic peptides cluster
Overview
Murepavadin (POL7080) is a synthetic cyclic beta-hairpin peptidomimetic derived from the host-defense peptide protegrin I. Unlike broad membrane-lytic peptides, it is Pseudomonas-specific, binding the outer-membrane protein LptD to disrupt lipopolysaccharide transport, and it has been studied against multidrug-resistant Pseudomonas aeruginosa. This page is educational and not medical advice.
Source & context
Biological / chemical source: Synthetic cyclic beta-hairpin peptidomimetic based on protegrin I
Primary research or clinical context: Investigational antibiotic studied for Pseudomonas aeruginosa infections
Novel target
Murepavadin binds LptD, an outer-membrane protein essential for lipopolysaccharide biogenesis in Gram-negative bacteria. This mechanism differs from classic antibiotics and retains activity against many carbapenemase-producing and colistin-resistant Pseudomonas isolates, making it a notable research example of narrow-spectrum, target-specific peptidomimetics.
Development status
Intravenous murepavadin completed phase II studies and entered phase III for hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Trials were affected by kidney-toxicity signals, and inhaled formulations have been explored. It is discussed here for scientific context, not as an approved therapy.
Structure & chemistry
Molecular identity & reference confidence
Source-supported reference
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- Murepavadin (source record; form not independently established)
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
- IUPHAR/BPS source snapshot · 2026-10-01
- PubChem molecular record · 2026-10-01
- Molecular formula
- C73H112N22O16
- Average reference mass
- ≈ 1,553.8
- PubChem CID: 91824766
- IUPHAR ligand: 10832
- ChEMBL: CHEMBL3946483
- DrugBank: DB14777
- CAS RN: 944252-63-5
- UNII: 0D02GRY87Z
Chemistry values: PubChem, IUPHAR/BPS Guide to Pharmacology · fetched 2026-10-01.
Clinical development snapshot
ClinicalTrials.gov lists 6 registered studies with “Murepavadin” as an intervention (snapshot 2026-10-01). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT03409679 | Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa | Phase 3 | terminated | 2019-08-28 |
| NCT03582007 | Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas | Phase 3 | terminated | 2019-08-28 |
| NCT02096328 | Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa | Phase 2 | completed | 2017-11-28 |
| NCT02096315 | Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis. | Phase 2 | terminated | 2017-02-01 |
| NCT02897869 | DDI Study to Investigate Interaction Between Amikacin and POL7080 | Phase 1 | completed | 2017-02-01 |
| NCT02110459 | Pharmacokinetics and Safety of POL7080 in Patients With Renal Impairment | Phase 1 | completed | 2016-06-17 |
Murepavadin — reconstitution calculator
Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.
Reference form: Murepavadin (source record; form not independently established)Average reference mass: 1,553.8 Da
Enter an amount to see the volume it corresponds to.
Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.
FAQ about Murepavadin
What is Murepavadin?+
Murepavadin (POL7080) is a synthetic cyclic beta-hairpin peptidomimetic derived from the host-defense peptide protegrin I. Unlike broad membrane-lytic peptides, it is Pseudomonas-specific, binding the outer-membrane protein LptD to disrupt lipopolysaccharide transport, and it has been studied against multidrug-resistant Pseudomonas aeruginosa. This page is educational and not medical advice.
What Canadian product status is recorded for Murepavadin?+
Canadian product status for Murepavadin has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of Murepavadin?+
Murepavadin is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.
Related peptides
References & further reading
- 1.Hernández-García et al. (2024). Unravelling the mechanisms causing murepavadin resistance in Pseudomonas aeruginosa: lipopolysaccharide alterations and its consequences. Front Cell Infect Microbiol
- 2.Martin-Loeches et al. (2018). Murepavadin: a new antibiotic class in the pipeline. Expert Rev Anti Infect Ther
- 3.Melchers et al. (2019). Pharmacokinetics and Pharmacodynamics of Murepavadin in Neutropenic Mouse Models. Antimicrob Agents Chemother
- 4.García-Gros et al. (2024). Synthesis of the Antimicrobial Peptide Murepavadin Using Novel Coupling Agents. Biomolecules
- 5.Sader et al. (2018). Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa. J Antimicrob Chemother
- 6.Ghassani et al. (2024). Mutations in genes lpxL1, bamA, and pmrB impair the susceptibility of cystic fibrosis strains of Pseudomonas aeruginosa to murepavadin. Antimicrob Agents Chemother
- 7.Wei et al. (2024). Murepavadin promotes the killing efficacies of aminoglycoside antibiotics against Pseudomonas aeruginosa by enhancing membrane potential. Antimicrob Agents Chemother
- 8.Díez-Aguilar et al. (2021). Anti-biofilm activity of murepavadin against cystic fibrosis Pseudomonas aeruginosa isolates. J Antimicrob Chemother
- 9.PubChem — compound summary for Murepavadin (CID 91824766)
- 10.Wikipedia — Murepavadin